证券记录 · 已归档季度
CSTL
Castle Biosciences, Inc. · Healthcare · Medical - Diagnostics & Research
11被追踪持有人
0Δ持有人
4.13M持有股份
$82.76M报告持仓市值
+1新建仓位
−1清仓
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 -14.6% · 净新建仓位 0.0% — 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q1 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 76 | -1 | 16.76M | $400.39M | +6 | −6 |
| Q1 2026 | 79 | -9 | 16.13M | $395.93M | +4 | −13 |
| Q4 2025 | 87 | +2 | 17.12M | $665.58M | +2 | — |
| Q3 2025 | 16 | 0 | 9.41M | $214.29M | +1 | −1 |
| Q2 2025 | 13 | -1 | 9.39M | $191.81M | — | −1 |
| Q1 2025 | 11 | 0 | 4.13M | $82.76M | +1 | −1 |
| Q4 2024 | 11 | +2 | 4.84M | $128.97M | +4 | −2 |
| Q3 2024 | 8 | 0 | 2.64M | $75.25M | — | — |
| Q2 2024 | 8 | — | 1.95M | $42.47M | — | — |
持有人 · Q1 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 828.53K | +14.7% | $16.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 828.53K | +14.7% | $16.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 828.53K | +14.7% | $16.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 828.53K | +14.7% | $16.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 828.53K | +14.7% | $16.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (被动) | 715.03K | +0.7% | $14.31M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 701.20K | +2.4% | $14.04M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Geode Capital Management ✦ (被动) | 649.85K | +3.5% | $13.01M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Geode Capital Management ✦ (被动) | 649.85K | +3.5% | $13.01M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 258.38K | -69.0% | $5.17M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 258.38K | -69.0% | $5.17M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | Millennium Management ✦ | 254.75K | -53.6% | $5.10M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 236.22K | -56.8% | $4.73M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 189.18K | +108.9% | $3.79M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 189.18K | +108.9% | $3.79M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 139.78K | 新增 | $2.80M | 0.0% | New | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 137.02K | +548.9% | $2.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 137.02K | +548.9% | $2.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 137.02K | +548.9% | $2.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 137.02K | +548.9% | $2.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 137.02K | +548.9% | $2.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 22 | T. Rowe Price ✦ | 23.70K | +4.4% | $475,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Two Sigma Investments | $2.80M | 0.0% |
已清仓
| Arrowstreet Capital | $770,265 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 186 持有人, 27.52M 股份, $653.08M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 17
Juvenal Tobin W
Officer · 1.73K 股 · $51,191
Aug 14
MAETZOLD DEREK J
Officer, Director · 1.10K 股 · $33,022
Aug 14
MAETZOLD DEREK J
Officer, Director · 2.71K 股 · $81,474
Aug 14
MAETZOLD DEREK J
Officer, Director · 2.31K 股 · $69,226
Aug 14
MAETZOLD DEREK J
Officer, Director · 278 股 · $8,346
Aug 14
Stokes Frank
Officer · 24.91K 股 · $741,511
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q1 2025 ·
方法论 ·
通过API获取此数据